Open Access

ARTICLE

A comparative analysis of prostate cancer pre-treatment characteristics stratified by age

Navin Shah¹, Vladimir Ioffe², Anish Kapur³

1 Mid-Atlantic Urology Associates, Greenbelt, Maryland, USA
2 21^st Century Oncology, Greenbelt, Maryland, USA
3 Aureus University School of Medicine, Orangestad, Aruba
Address correspondence to Dr. Vladimir Ioffe, 602 S. Atwood Road, Suite 105, Bel Air, MD 21014 USA

Canadian Journal of Urology 2014, 21(2), 7213-7216.

Abstract

Introduction: To compare the pretreatment characteristics of prostate cancer, prostate-specific antigen (PSA), digital rectal examination (DRE) and Gleason sum score (GSS) by the American Urological Association (AUA) stratified age groups, <55, 55-69 and ≥70 years old.
Materials and methods: A retrospective analysis of 402 sequential prostate cancer patients, who had transrectal ultrasound guided 12 core prostate biopsy for either elevated PSA (over 2.5 ng/mL) or positive DRE or both during a three year period, 2010 to 2012. There were 36 patients <55 years, 226 patients 55 to 69 years and 140 patients ≥70 years (range 44-78 years old). This study was conceptualized after the AUA released prostate cancer screening guidelines in which men ≥70 were deleted from screening.
Results: Overall, compared with patients <70 years old, we found that in patients ≥70 years old: 1) 60.7% had high GSS (7-10) (p = 0.0234); 2) 39.3% had low GSS (6) (p = 0.0234); 3) 31% had PSA level ≥10 ng/mL (p = 0.0010) and 4) 69.1% had high GSS (7-10) in the presence of a positive DRE (p = 0.0278).
Conclusion: Patients ≥70 years old had a higher incidence of high GSS (7-10) compared to prostate cancer patients <70 years old. Patients ≥70 years old who also had a positive DRE had the highest incidence of high GSS.

---

Keywords

---